Author | Mack Roach III, MD, FACR


Radium-223 vs EBRT for Multiple Painful Bone Metastases: Is Less More?

April 15, 2014

There is no question that radiopharmaceuticals have a role in the management of patients with metastatic bone disease. There is also no question that fractionated external beam radiotherapy (EBRT) is highly effective and generally well tolerated when delivered with large open or focal fields.

Radium-223: Down to the Bone, and Less Is More

April 17, 2012

Radium-223 is a promising agent that represents a new class of alpha pharmaceuticals that gets down to the site of bony metastases. The limited side-effect profile potentially allows for repeat administration to increase durability of pain control, and for its use in combination with novel biologic and chemotherapeutic agents.

Benefits and Pitfalls of Prostate Cancer Screening: “No Proof of Benefit” Does Not Equal “Proof of No Benefit”

May 12, 2011

Prostate cancer screening using prostate-specific antigen (PSA) testing has been a contentious subject.

Who, When, Where, and How: Salvage Prostate Cancer With Radiotherapy

July 15, 2010

Despite the common use of postoperative radiotherapy (RT) in patients managed initially with radical prostatectomy (RP), a number of questions remain. Raldow and colleagues build their arguments around three randomized trials that indicated a significant benefit of immediate adjuvant radiotherapy in patients with high-risk features.